<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: High white blood cell (WBC) predicted <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-associated mortality and renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) inhibitors have immunomodulating effects </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesize that <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors may reduce <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk associated with high WBC in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A prospective cohort of 4570 Chinese T2DM patients, free of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> at enrolment, were analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>Biological interaction between WBC groups and use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors was estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP) and synergy index (S) </plain></SENT>
<SENT sid="4" pm="."><plain>RERI&gt;0, AP&gt;0 or S&gt;1 indicates biological interaction </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: During 4.89 years of follow-up, 205 (4.49%) patients developed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>WBC &gt; or = 8.2 x 10(9) counts/L plus non-use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors was associated with elevated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks in multivariable models </plain></SENT>
<SENT sid="7" pm="."><plain>The RERI and AP for interaction between WBC &gt; or = 8.2 x 10(9) counts/L and non-use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors were, respectively, 1.26 (95% CI: 0.22-2.31) and 0.50 (0.23-0.78) </plain></SENT>
<SENT sid="8" pm="."><plain>In patients with WBC &gt; or = 8.2 x 10(9) counts/L, use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors was associated with 64% (31-81%) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk reduction in multivariable analysis </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In T2DM, increased WBC predicts <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> while use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors may reduce <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks associated with high WBC count </plain></SENT>
</text></document>